Towards an alternative testing strategy for nanomaterials used in nanomedicine: Lessons from NanoTEST

M Dusinska; S Boland; M Saunders; L Juillerat-Jeanneret; L Tran; G Pojana; A Marcomini; K Volkovova; J Tulinska; Lisbeth E. Knudsen; L Gombau; M Whelan; A R Collins; F Marano; C Housiadas; D Bilanicova; B Halamoda Kenzaoui; S Correia Carreira; Z Magdolenova; L M Fjellsbø; A Huk; R Handy; L Walker; M Barancokova; A Bartonova; E Burello; J Castell; H Cowie; M Drlickova; R Guadagnini; G Harris; M Harju; E S Heimstad; M Hurbankova; A Kazimirova; Z Kovacikova; M Kuricova; A Liskova; A Milcamps; E Neubauerova; T Palosaari; P Papazafiri; M Pilou; M S Poulsen; B Ross; E Runden-Pran; K Sebekova; M Staruchova; D Vallotto; A Worth

doi:10.3109/17435390.2014.991431

Towards an alternative testing strategy for nanomaterials used in nanomedicine: Lessons from NanoTEST

M Dusinska, S Boland, M Saunders, L Juillerat-Jeanneret, L Tran, G Pojana, A Marcomini, K Volkovova, J Tulinska, Lisbeth E. Knudsen, L Gombau, M Whelan, A R Collins, F Marano, C Housiadas, D Bilanicova, B Halamoda Kenzaoui, S Correia Carreira, Z Magdolenova, L M FjellsbøA Huk, R Handy, L Walker, M Barancokova, A Bartonova, E Burello, J Castell, H Cowie, M Drlickova, R Guadagnini, G Harris, M Harju, E S Heimstad, M Hurbankova, A Kazimirova, Z Kovacikova, M Kuricova, A Liskova, A Milcamps, E Neubauerova, T Palosaari, P Papazafiri, M Pilou, M S Poulsen, B Ross, E Runden-Pran, K Sebekova, M Staruchova, D Vallotto, A Worth

47 Citationer (Scopus)

Abstract

In spite of recent advances in describing the health outcomes of exposure to nanoparticles (NPs), it still remains unclear how exactly NPs interact with their cellular targets. Size, surface, mass, geometry, and composition may all play a beneficial role as well as causing toxicity. Concerns of scientists, politicians and the public about potential health hazards associated with NPs need to be answered. With the variety of exposure routes available, there is potential for NPs to reach every organ in the body but we know little about the impact this might have. The main objective of the FP7 NanoTEST project ( www.nanotest-fp7.eu ) was a better understanding of mechanisms of interactions of NPs employed in nanomedicine with cells, tissues and organs and to address critical issues relating to toxicity testing especially with respect to alternatives to tests on animals. Here we describe an approach towards alternative testing strategies for hazard and risk assessment of nanomaterials, highlighting the adaptation of standard methods demanded by the special physicochemical features of nanomaterials and bioavailability studies. The work has assessed a broad range of toxicity tests, cell models and NP types and concentrations taking into account the inherent impact of NP properties and the effects of changes in experimental conditions using well-characterized NPs. The results of the studies have been used to generate recommendations for a suitable and robust testing strategy which can be applied to new medical NPs as they are developed.

Originalsprog	Engelsk
Tidsskrift	Nanotoxicology
Vol/bind	9
Udgave nummer	Supplement 1
Sider (fra-til)	118-32
Antal sider	15
ISSN	1743-5390
DOI	https://doi.org/10.3109/17435390.2014.991431
Status	Udgivet - 1 maj 2015

Adgang til dokumentet

10.3109/17435390.2014.991431

Citationsformater

Dusinska, M., Boland, S., Saunders, M., Juillerat-Jeanneret, L., Tran, L., Pojana, G., Marcomini, A., Volkovova, K., Tulinska, J., Knudsen, L. E., Gombau, L., Whelan, M., Collins, A. R., Marano, F., Housiadas, C., Bilanicova, D., Halamoda Kenzaoui, B., Correia Carreira, S., Magdolenova, Z., ... Worth, A. (2015). Towards an alternative testing strategy for nanomaterials used in nanomedicine: Lessons from NanoTEST. Nanotoxicology, 9(Supplement 1), 118-32. https://doi.org/10.3109/17435390.2014.991431

Dusinska, M, Boland, S, Saunders, M, Juillerat-Jeanneret, L, Tran, L, Pojana, G, Marcomini, A, Volkovova, K, Tulinska, J, Knudsen, LE, Gombau, L, Whelan, M, Collins, AR, Marano, F, Housiadas, C, Bilanicova, D, Halamoda Kenzaoui, B, Correia Carreira, S, Magdolenova, Z, Fjellsbø, LM, Huk, A, Handy, R, Walker, L, Barancokova, M, Bartonova, A, Burello, E, Castell, J, Cowie, H, Drlickova, M, Guadagnini, R, Harris, G, Harju, M, Heimstad, ES, Hurbankova, M, Kazimirova, A, Kovacikova, Z, Kuricova, M, Liskova, A, Milcamps, A, Neubauerova, E, Palosaari, T, Papazafiri, P, Pilou, M, Poulsen, MS, Ross, B, Runden-Pran, E, Sebekova, K, Staruchova, M, Vallotto, D & Worth, A 2015, 'Towards an alternative testing strategy for nanomaterials used in nanomedicine: Lessons from NanoTEST', Nanotoxicology, bind 9, nr. Supplement 1, s. 118-32. https://doi.org/10.3109/17435390.2014.991431

@article{1b7a9f24865642be888c6e98b8e65bc4,

title = "Towards an alternative testing strategy for nanomaterials used in nanomedicine: Lessons from NanoTEST",

abstract = "In spite of recent advances in describing the health outcomes of exposure to nanoparticles (NPs), it still remains unclear how exactly NPs interact with their cellular targets. Size, surface, mass, geometry, and composition may all play a beneficial role as well as causing toxicity. Concerns of scientists, politicians and the public about potential health hazards associated with NPs need to be answered. With the variety of exposure routes available, there is potential for NPs to reach every organ in the body but we know little about the impact this might have. The main objective of the FP7 NanoTEST project ( www.nanotest-fp7.eu ) was a better understanding of mechanisms of interactions of NPs employed in nanomedicine with cells, tissues and organs and to address critical issues relating to toxicity testing especially with respect to alternatives to tests on animals. Here we describe an approach towards alternative testing strategies for hazard and risk assessment of nanomaterials, highlighting the adaptation of standard methods demanded by the special physicochemical features of nanomaterials and bioavailability studies. The work has assessed a broad range of toxicity tests, cell models and NP types and concentrations taking into account the inherent impact of NP properties and the effects of changes in experimental conditions using well-characterized NPs. The results of the studies have been used to generate recommendations for a suitable and robust testing strategy which can be applied to new medical NPs as they are developed.",

author = "M Dusinska and S Boland and M Saunders and L Juillerat-Jeanneret and L Tran and G Pojana and A Marcomini and K Volkovova and J Tulinska and Knudsen, {Lisbeth E.} and L Gombau and M Whelan and Collins, {A R} and F Marano and C Housiadas and D Bilanicova and {Halamoda Kenzaoui}, B and {Correia Carreira}, S and Z Magdolenova and Fjellsb{\o}, {L M} and A Huk and R Handy and L Walker and M Barancokova and A Bartonova and E Burello and J Castell and H Cowie and M Drlickova and R Guadagnini and G Harris and M Harju and Heimstad, {E S} and M Hurbankova and A Kazimirova and Z Kovacikova and M Kuricova and A Liskova and A Milcamps and E Neubauerova and T Palosaari and P Papazafiri and M Pilou and Poulsen, {M S} and B Ross and E Runden-Pran and K Sebekova and M Staruchova and D Vallotto and A Worth",

year = "2015",

month = may,

day = "1",

doi = "10.3109/17435390.2014.991431",

language = "English",

volume = "9",

pages = "118--32",

journal = "Nanotoxicology",

issn = "1743-5390",

publisher = "Informa Healthcare",

number = "Supplement 1",

}

TY - JOUR

T1 - Towards an alternative testing strategy for nanomaterials used in nanomedicine

T2 - Lessons from NanoTEST

AU - Dusinska, M

AU - Boland, S

AU - Saunders, M

AU - Juillerat-Jeanneret, L

AU - Tran, L

AU - Pojana, G

AU - Marcomini, A

AU - Volkovova, K

AU - Tulinska, J

AU - Knudsen, Lisbeth E.

AU - Gombau, L

AU - Whelan, M

AU - Collins, A R

AU - Marano, F

AU - Housiadas, C

AU - Bilanicova, D

AU - Halamoda Kenzaoui, B

AU - Correia Carreira, S

AU - Magdolenova, Z

AU - Fjellsbø, L M

AU - Huk, A

AU - Handy, R

AU - Walker, L

AU - Barancokova, M

AU - Bartonova, A

AU - Burello, E

AU - Castell, J

AU - Cowie, H

AU - Drlickova, M

AU - Guadagnini, R

AU - Harris, G

AU - Harju, M

AU - Heimstad, E S

AU - Hurbankova, M

AU - Kazimirova, A

AU - Kovacikova, Z

AU - Kuricova, M

AU - Liskova, A

AU - Milcamps, A

AU - Neubauerova, E

AU - Palosaari, T

AU - Papazafiri, P

AU - Pilou, M

AU - Poulsen, M S

AU - Ross, B

AU - Runden-Pran, E

AU - Sebekova, K

AU - Staruchova, M

AU - Vallotto, D

AU - Worth, A

PY - 2015/5/1

Y1 - 2015/5/1

N2 - In spite of recent advances in describing the health outcomes of exposure to nanoparticles (NPs), it still remains unclear how exactly NPs interact with their cellular targets. Size, surface, mass, geometry, and composition may all play a beneficial role as well as causing toxicity. Concerns of scientists, politicians and the public about potential health hazards associated with NPs need to be answered. With the variety of exposure routes available, there is potential for NPs to reach every organ in the body but we know little about the impact this might have. The main objective of the FP7 NanoTEST project ( www.nanotest-fp7.eu ) was a better understanding of mechanisms of interactions of NPs employed in nanomedicine with cells, tissues and organs and to address critical issues relating to toxicity testing especially with respect to alternatives to tests on animals. Here we describe an approach towards alternative testing strategies for hazard and risk assessment of nanomaterials, highlighting the adaptation of standard methods demanded by the special physicochemical features of nanomaterials and bioavailability studies. The work has assessed a broad range of toxicity tests, cell models and NP types and concentrations taking into account the inherent impact of NP properties and the effects of changes in experimental conditions using well-characterized NPs. The results of the studies have been used to generate recommendations for a suitable and robust testing strategy which can be applied to new medical NPs as they are developed.

AB - In spite of recent advances in describing the health outcomes of exposure to nanoparticles (NPs), it still remains unclear how exactly NPs interact with their cellular targets. Size, surface, mass, geometry, and composition may all play a beneficial role as well as causing toxicity. Concerns of scientists, politicians and the public about potential health hazards associated with NPs need to be answered. With the variety of exposure routes available, there is potential for NPs to reach every organ in the body but we know little about the impact this might have. The main objective of the FP7 NanoTEST project ( www.nanotest-fp7.eu ) was a better understanding of mechanisms of interactions of NPs employed in nanomedicine with cells, tissues and organs and to address critical issues relating to toxicity testing especially with respect to alternatives to tests on animals. Here we describe an approach towards alternative testing strategies for hazard and risk assessment of nanomaterials, highlighting the adaptation of standard methods demanded by the special physicochemical features of nanomaterials and bioavailability studies. The work has assessed a broad range of toxicity tests, cell models and NP types and concentrations taking into account the inherent impact of NP properties and the effects of changes in experimental conditions using well-characterized NPs. The results of the studies have been used to generate recommendations for a suitable and robust testing strategy which can be applied to new medical NPs as they are developed.

U2 - 10.3109/17435390.2014.991431

DO - 10.3109/17435390.2014.991431

M3 - Journal article

C2 - 25923349

SN - 1743-5390

VL - 9

SP - 118

EP - 132

JO - Nanotoxicology

JF - Nanotoxicology

IS - Supplement 1

ER -

Towards an alternative testing strategy for nanomaterials used in nanomedicine: Lessons from NanoTEST

Abstract

Adgang til dokumentet

Fingeraftryk

Citationsformater